Pharmaceutical Technology22 天
Sunobinop tosylate by Imbrium Therapeutics for Insomnia: Likelihood of Approval
Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase II for Insomnia. According to GlobalData, Phase II drugs for Insomnia have a 44% phase transition ...
C&EN12 天
Methodologies for the Formation of 2-Substituted Oxetanes: Synthesis of (S)-Oxetan-2 ...
Chemical Research and Development, Pfizer, Discovery Park, Sandwich CT13 9NJ, Kent, U.K.